Categories Earnings, Health Care

Arbutus Biopharma (ABUS): FY19 Earnings Snapshot

— Arbutus Biopharma Corporation (NASDAQ:ABUS) reported a net loss of $164.9 million or $2.89 per share for fiscal 2019, compared to a loss of $67.2 million or $1.21 per share last year.

— Total revenues edged up to $6.01 million from $5.9 million in 2018

— Research and development expenses were almost unchanged year-over-year at $57.6 million in fiscal 2019

— Achieved progress in a focused discovery effort on follow-on compounds for the current HBV pipeline

— On track to advance a next-generation oral HBV specific RNA-destabilizer with chemical scaffolds distinct from AB-452 through lead optimization

— Ended 2019 with $90.8 million in cash, cash equivalents and short-term investments

— Expects to utilize between $54 to $58 million of cash and investments to fund operations in 2020

We’re on Apple News! Follow us to receive the latest stock market, earnings and financial news at your fingertips

Most Popular

MCD Earnings: McDonald’s comp sales up 12.6% in Q4; profit increases

Fast-food chain McDonald’s Corporation (NYSE: MCD) on Tuesday reported an increase in adjusted earnings for the fourth quarter of 2022 when its revenues remained broadly unchanged. The company said fourth-quarter

GM Earnings: All you need to know about General Motors Q4 2022 earnings results

General Motors Co. (NYSE: GM) reported fourth quarter 2022 earnings results today. Revenue increased 28.4% year-over-year to $43.1 billion. Net income attributable to stockholders increased 14.8% to $2 billion while EPS rose 19.8%

CAT Earnings: Highlights of Caterpillar’s Q4 2022 results

Construction-equipment manufacturer Caterpillar Inc. (NYSE: CAT) reported double-digit growth in fourth-quarter revenues and adjusted earnings. Adjusted net profit increased to $3.86 per share in the December quarter from $2.69 per

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top